Baek Jin Ho, Kim Juhyung, Baek Dong Won, Chang Eunhye, Kim Hye Jin, Park Su Yeon, Park Jun Seok, Choi Gyu Seog, Kang Byung Woog, Kim Jong Gwang
Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Kyungpook National University Cancer Research Institute, Daegu, Republic of Korea.
Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Cancer Diagn Progn. 2022 Jan 3;2(1):78-83. doi: 10.21873/cdp.10079. eCollection 2022 Jan-Feb.
This study evaluated the clinical implication of KRAS proto-oncogene, GTPase (KRAS) mutation variants in patients with resected colon cancer (CC).
We retrospectively reviewed 482 patients diagnosed with CC who underwent curative surgical resection at Kyungpook National University Chilgok Hospital. The inclusion criteria were: Pathologically diagnosed with primary CC; stage I-III CC according to the 7th edition of American Joint Committee on Cancer staging system; and with available test results for KRAS mutation status. In total, 345 patients met these criteria and were included in this study.
Among the 345 patients, 140 (40.6%) exhibited KRAS mutations, with their incidences as follows: 90/140 (64.3%) in exon 2 codon 12, 37/140 (26.4%) in exon 2 codon 13, 1/140 (0.1%) in exon 3 codon 59, 7/140 (5.0%) in exon 3 codon 61, and 5/140 (3.6%) in exon 4 codon 146. KRAS mutation status was not a significant prognostic factor for disease-free survival or overall survival. Although there were no significant differences in survival between patients with exon 2 codon 12 and exon 2 codon 13 mutations, poorer disease-free survival (p=0.085) and overall survival (p=0.005) were seen in those with exon 3 codon 61 mutation than in others.
KRAS mutation status was not correlated with survival, but exon 3 codon 61 mutation might be a factor for poor prognosis in patients after resection of CC.
本研究评估了RAS原癌基因、GTP酶（KRAS）突变变体在接受结肠癌（CC）切除患者中的临床意义。
我们回顾性分析了482例在庆北国立大学칠곡医院接受根治性手术切除的CC患者。纳入标准为：经病理诊断为原发性CC；根据美国癌症联合委员会第7版癌症分期系统为I-III期CC；且有KRAS突变状态的可用检测结果。共有345例患者符合这些标准并纳入本研究。
在345例患者中，140例（40.6%）出现KRAS突变，其发生率如下：外显子2密码子12处90/140（64.3%），外显子2密码子13处37/140（26.4%），外显子3密码子59处1/140（0.1%），外显子3密码子61处7/140（5.0%），外显子4密码子146处5/140（3.6%）。KRAS突变状态不是无病生存期或总生存期的显著预后因素。虽然外显子2密码子12和外显子2密码子13突变患者的生存率无显著差异，但外显子3密码子61突变患者的无病生存期（p=0.085）和总生存期（p=0.005）较其他患者差。
KRAS突变状态与生存率无关，但外显子3密码子61突变可能是CC切除术后患者预后不良的一个因素。
